Targeting homologous recombination deficiency in uterine leiomyosarcoma

Table 2 Outcomes of five individuals with uLMS treated with PARPi

Patient	Time on PARPi	OS^a
^cuLMS#122 olaparib; + cisplatin; ± RT	49 mo^b	49 mo^b
^duLMS#227 olaparib (ceased); chemotherapy	4 mo	9 mo
^cuLMS#347 olaparib; RT	19 mo^b	19 mo^b
^cuLMS#438 olaparib; + carboplatin	19 mo^b	19 mo^b
^cuLMS#683 olaparib;	3 mo^b	3 mo^b

ISSN: 1756-9966